Inflammation and the two-hit hypothesis of schizophrenia

Neuroscience and Biobehavioral Reviews

Volumn 38, Issue , 2014, Pages 72-93

  Feigenson, Keith A ^a   Kusnecov, Alex W ^a   Silverstein, Steven M ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Animal Models; Biomarkers; Comorbidity; Infection; Inflammation; Schizophrenia

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DOPAMINE 2 RECEPTOR; ERYTHROPOIETIN; ESTROGEN; GLUTAMIC ACID; KYNURENINE; MEMBRANE PHOSPHOLIPID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; TETRACYCLINE;

AUTOIMMUNE DISEASE; CANCER RISK; COGNITIVE DEFECT; COMORBIDITY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DOPAMINERGIC SYSTEM; ENDOGENOUS RETROVIRUS; ENVIRONMENTAL FACTOR; GABAERGIC SYSTEM; HUMAN; INFLAMMATION; INTRAUTERINE INFECTION; MICROGLIA; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PSYCHOSIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SENSORY GATING; SEX DIFFERENCE; TOXOPLASMOSIS;

ANIMAL MODELS; BIOMARKERS; COMORBIDITY; INFECTION; INFLAMMATION; SCHIZOPHRENIA;

ANIMALS; COMORBIDITY; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; MODELS, NEUROLOGICAL; SCHIZOPHRENIA;

EID: 84888794751     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.11.006     Document Type: Review

References (399)

1. Abazyan B., Nomura J., Kannan G., Ishizuka K., Tamashiro K.L., Nucifora F., Pogorelov V., Ladenheim B., Yang C., Krasnova I.N., Cadet J.L., Pardo C., Mori S., Kamiya A., Vogel M.W., Sawa A., Ross C.A., Pletnikov M.V. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biological Psychiatry 2010, 68:1172-1181.
2. Abel K.M., Drake R., Goldstein J.M. Sex differences in schizophrenia. International Review of Psychiatry 2010, 22:417-428.
3. Adell A., Jimenez-Sanchez L., Lopez-Gil X., Romon T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophrenia Bulletin 2012, 38:9-14.
4. Ahmad A.S., Ahmad M., de Brum-Fernandes A.J., Dore S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Research 2005, 1066:71-77.
5. Ahmari S.E., Risbrough V.B., Geyer M.A., Simpson H.B. Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology 2012, 37:1216-1223.
6. Akaike A., Kaneko S., Tamura Y., Nakata N., Shiomi H., Ushikubi F., Narumiya S. Prostaglandin E2 protects cultured cortical neurons against N-methyl-d-aspartate receptor-mediated glutamate cytotoxicity. Brain Research 1994, 663:237-243.
7. Akter K., Gallo D.A., Martin S.A., Myronyuk N., Roberts R.T., Stercula K., Raffa R.B. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. Journal of Clinical Pharmacy and Therapeutics 2012, 37:132-139.
8. Alexander K.S., Wu H.Q., Schwarcz R., Bruno J.P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 2012, 220:627-637.
9. Allan C.L., Cardno A.G., Rijsdijk F.V., Kalidindi S., Farmer A., Murray R.M., McGuffin P. Twin study of illness history variables in psychosis. Schizophrenia Research 2009, 115:237-244.
10. Alvarado-Esquivel C., Torres-Castorena A., Liesenfeld O., Estrada-Martinez S., Urbina-Alvarez J.D. High seroprevalence of Toxoplasma gondii infection in a subset of Mexican patients with work accidents and low socioeconomic status. Parasites and Vectors 2012, 5:13.
11. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry 2010, 67:146-154.
12. Anderson G., Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 42:5-19.
13. Arevalo M.A., Diz-Chaves Y., Santos-Galindo M., Bellini M.J., Garcia-Segura L.M. Selective oestrogen receptor modulators decrease the inflammatory response of glial cells. Journal of Neuroendocrinology 2012, 24:183-190.
14. Aronsson F., Lannebo C., Paucar M., Brask J., Kristensson K., Karlsson H. Persistence of viral RNA in the brain of offspring to mice infected with influenza A/WSN/33 virus during pregnancy. Journal of Neurovirology 2002, 8:353-357.
15. Asp L., Holtze M., Powell S.B., Karlsson H., Erhardt S. Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. International Journal of Neuropsychopharmacology 2010, 13:475-485.
16. Asp L., Johansson A.S., Mann A., Owe-Larsson B., Urbanska E.M., Kocki T., Kegel M., Engberg G., Lundkvist G.B., Karlsson H. Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. Journal of Inflammation (London) 2011, 8:25.
17. Baharnoori M., Bhardwaj S.K., Srivastava L.K. Effect of maternal lipopolysaccharide administration on the development of dopaminergic receptors and transporter in the rat offspring. PLoS ONE 2013, 8:e54439.
18. Bale T.L., Baram T.Z., Brown A.S., Goldstein J.M., Insel T.R., McCarthy M.M., Nemeroff C.B., Reyes T.M., Simerly R.B., Susser E.S., Nestler E.J. Early life programming and neurodevelopmental disorders. Biological Psychiatry 2010, 68:314-319.
19. Banerjee J., Alkondon M., Albuquerque E.X. Kynurenic acid inhibits glutamatergic transmission to CA1 pyramidal neurons via alpha7 nAChR-dependent and -independent mechanisms. Biochemical Pharmacology 2012, 84:1078-1087.
20. Banerjee J., Alkondon M., Pereira E.F., Albuquerque E.X. Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. Journal of Pharmacology and Experimental Therapeutics 2012, 341:500-509.
21. Barak Y., Achiron A., Mandel M., Mirecki I., Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer 2005, 104:2817-2821.
22. Bartzokis G., Lu P.H., Nuechterlein K.H., Gitlin M., Doi C., Edwards N., Lieu C., Altshuler L.L., Mintz J. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophrenia Research 2007, 93:13-22.
23. Bauer S., Kerr B.J., Patterson P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nature Reviews Neuroscience 2007, 8:221-232.
24. Bayer T.A., Falkai P., Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the two hit hypothesis. Journal of Psychiatric Research 1999, 33:543-548.
25. Beary M., Hodgson R., Wildgust H.J. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. Journal of Psychopharmacology 2012, 26:52-61.
26. Bechter K. Updating the mild encephalitis hypothesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 42:71-91.
27. Bechter K., Reiber H., Herzog S., Fuchs D., Tumani H., Maxeiner H.G. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. Journal of Psychiatric Research 2010, 44:321-330.
28. Begemann M.J., Dekker C.F., van Lunenburg M., Sommer I.E. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophrenia Research 2012, 141:179-184.
29. Benedusi V., Meda C., Della Torre S., Monteleone G., Vegeto E., Maggi A. A lack of ovarian function increases neuroinflammation in aged mice. Endocrinology 2012, 153:2777-2788.
30. Bennett M.R. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Progress in Neurobiology 2011, 95:275-300.
31. Benros M.E., Laursen T.M., Dalton S.O., Mortensen P.B. Psychiatric disorder as a first manifestation of cancer: a 10-year population-based study. International Journal of Cancer 2009, 124:2917-2922.
32. Benros M.E., Mortensen P.B., Eaton W.W. Autoimmune diseases and infections as risk factors for schizophrenia. Annals of the New York Academy of Sciences 2012, 1262:56-66.
33. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. American Journal of Psychiatry 2011, 168:1303-1310.
34. Bentsen H., Solberg D.K., Refsum H., Bohmer T. Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins Leukotrienes and Essential Fatty Acids 2012, 87:35-41.
35. Bentsen H., Solberg D.K., Refsum H., Gran J.M., Bohmer T., Torjesen P.A., Halvorsen O., Lingjaerde O. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biological Psychiatry 2011, 70:97-105.
36. Beppu K., Kosai Y., Kido M.A., Akimoto N., Mori Y., Kojima Y., Fujita K., Okuno Y., Yamakawa Y., Ifuku M., Shinagawa R., Nabekura J., Sprengel R., Noda M. Expression, subunit composition, and function of AMPA-type glutamate receptors are changed in activated microglia; possible contribution of GluA2 (GluR-B)-deficiency under pathological conditions. Glia 2013, 61:881-891.
37. Berger J.V., Dumont A.O., Focant M.C., Vergouts M., Sternotte A., Calas A.G., Goursaud S., Hermans E. Opposite regulation of metabotropic glutamate receptor 3 and metabotropic glutamate receptor 5 by inflammatory stimuli in cultured microglia and astrocytes. Neuroscience 2012, 205:29-38.
38. Beumer W., Gibney S.M., Drexhage R.C., Pont-Lezica L., Doorduin J., Klein H.C., Steiner J., Connor T.J., Harkin A., Versnel M.A., Drexhage H.A. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology 2012, 92:959-975.
39. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998, 391:281-285.
40. Bhadra R., Cobb D.A., Weiss L.M., Khan I.A. Psychiatric disorders in toxoplasma seropositive patients - the CD8 connection. Schizophrenia Bulletin 2013, 39:485-489.
41. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Frontiers in Behavioral Neuroscience 2009, 3:14.
42. Bilbo S.D., Schwarz J.M. The immune system and developmental programming of brain and behavior. Frontiers in Neuroendocrinology 2012, 33:267-286.
43. Bitanihirwe B.K., Peleg-Raibstein D., Mouttet F., Feldon J., Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010, 35:2462-2478.
44. Bland S.T., Beckley J.T., Young S., Tsang V., Watkins L.R., Maier S.F., Bilbo S.D. Enduring consequences of early-life infection on glial and neural cell genesis within cognitive regions of the brain. Brain, Behavior, and Immunity 2010, 24:329-338.
45. Blank T., Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2013, 61:62-70.
46. Blomstrom A., Karlsson H., Wicks S., Yang S., Yolken R.H., Dalman C. Maternal antibodies to infectious agents and risk for non-affective psychoses in the offspring - a matched case-control study. Schizophrenia Research 2012, 140:25-30.
47. Boissier M.C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity 2012, 39:222-228.
48. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain, Behavior, and Immunity 2010, 24:881-897.
49. Boksa P. Abnormal synaptic pruning in schizophrenia: urban myth or reality?. Journal of Psychiatry and Neuroscience 2012, 37:75-77.
50. Bonnot O., Anderson G.M., Cohen D., Willer J.C., Tordjman S. Are patients with schizophrenia insensitive to pain? A reconsideration of the question. Clinical Journal of Pain 2009, 25:244-252.
51. Braff D.L., Ryan J., Rissling A.J., Carpenter W.T. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophrenia Bulletin 2013, 39:751-753.
52. Brann D.W., Dhandapani K., Wakade C., Mahesh V.B., Khan M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007, 72:381-405.
53. Brodziak A., Ziolko E., Muc-Wierzgon M., Nowakowska-Zajdel E., Kokot T., Klakla K. The role of human endogenous retroviruses in the pathogenesis of autoimmune diseases. Medical Science Monitor 2012, 18:RA80-RA88.
54. Bronte V., Mocellin S. Suppressive influences in the immune response to cancer. Journal of Immunotherapy 2009, 32:1-11.
55. Brown A.S. The environment and susceptibility to schizophrenia. Progress in Neurobiology 2011, 93:23-58.
56. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., Babulas V.P., Susser E.S. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Archives of General Psychiatry 2004, 61:774-780.
57. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. American Journal of Psychiatry 2010, 167:261-280.
58. Brown A.S., Patterson P.H. Maternal infection and schizophrenia: implications for prevention. Schizophrenia Bulletin 2011, 37:284-290.
59. Brown A.S., Schaefer C.A., Quesenberry C.P., Liu L., Babulas V.P., Susser E.S. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. American Journal of Psychiatry 2005, 162:767-773.
60. Broz P., Monack D.M. Newly described pattern recognition receptors team up against intracellular pathogens. Nature Reviews Immunology 2013, 13:551-565.
61. Bruce-Keller A.J., Keeling J.L., Keller J.N., Huang F.F., Camondola S., Mattson M.P. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 2000, 141:3646-3656.
62. Buka S.L., Cannon T.D., Torrey E.F., Yolken R.H. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biological Psychiatry 2008, 63:809-815.
63. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Bernstein D., Yolken R.H. Maternal infections and subsequent psychosis among offspring. Archives of General Psychiatry 2001, 58:1032-1037.
64. Burt M.A., Tse Y.C., Boksa P., Wong T.P. Prenatal immune activation interacts with stress and corticosterone exposure later in life to modulate N-methyl-d-aspartate receptor synaptic function and plasticity. International Journal of Neuropsychopharmacology 2013, 1-14.
65. Bushe C.J., Bradley A.J., Wildgust H.J., Hodgson R.E. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophrenia Research 2009, 114:6-16.
66. Calder P.C. n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proceedings of the Nutrition Society 2013, 72:326-336.
67. Cao D., Kevala K., Kim J., Moon H.S., Jun S.B., Lovinger D., Kim H.Y. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. Journal of Neurochemistry 2009, 111:510-521.
68. Carlson N.G., Rojas M.A., Black J.D., Redd J.W., Hille J., Hill K.E., Rose J.W. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. Journal of Neuroinflammation 2009, 6:5.
69. Carmona L., Cross M., Williams B., Lassere M., March L. Rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology 2010, 24:733-745.
70. Carver J.D., Benford V.J., Han B., Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Research Bulletin 2001, 56:79-85.
71. Casado M., Ascher P. Opposite modulation of NMDA receptors by lysophospholipids and arachidonic acid: common features with mechanosensitivity. Journal of Physiology 1998, 513(Pt 2):317-330.
72. Catts V.S., Catts S.V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?. Schizophrenia Research 2000, 41:405-415.
73. Catts V.S., Catts S.V., O'Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatrica Scandinavica 2008, 117:323-336.
74. Cazevieille C., Muller A., Meynier F., Dutrait N., Bonne C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochemistry International 1994, 24:395-398.
75. Chan W.Y., Chia M.Y., Yang G.L., Woon P.S., Sitoh Y.Y., Collinson S.L., Nowinski W.L., Sim K. Duration of illness, regional brain morphology and neurocognitive correlates in schizophrenia. Annals of the Academy of Medicine, Singapore 2009, 38:388.
76. Chen S.J., Chao Y.L., Chen C.Y., Chang C.M., Wu E.C., Wu C.S., Yeh H.H., Chen C.H., Tsai H.J. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. British Journal of Psychiatry 2012, 200:374-380.
77. Chen Y.J., Lin G.M., Li Y.H. Cancer risk before schizophrenia diagnosis in Taiwan, 1995-2009. Schizophrenia Bulletin 2013, 39:729-731.
78. Chung W.S., Barres B.A. The role of glial cells in synapse elimination. Current Opinion in Neurobiology 2012, 22:438-445.
79. Clarke M.C., Kelleher I., Clancy M., Cannon M. Predicting risk and the emergence of schizophrenia. Psychiatric Clinics of North America 2012, 35:585-612.
80. Coe C.L. Psychosocial factors and immunity in nonhuman primates: a review. Psychosomatic Medicine 1993, 55:298-308.
81. Cohen M., Dembling B., Schorling J. The association between schizophrenia and cancer: a population-based mortality study. Schizophrenia Research 2002, 57:139-146.
82. Condray R., Yao J.K. Cognition, dopamine and bioactive lipids in schizophrenia. Frontiers in Bioscience (Scholar Edition) 2011, 3:298-330.
83. Condray R., Yao J.K., Steinhauer S.R., van Kammen D.P., Reddy R.D., Morrow L.A. Semantic memory in schizophrenia: association with cell membrane essential fatty acids. Schizophrenia Research 2008, 106:13-28.
84. Corvin A., Buchanan R.W., Carpenter W.T., Kennedy J.L., Keshavan M.S., MacDonald A., Sass L., Wessa M. Which aspects of heterogeneity are useful to translational success?. Schizophrenia: Evolution and Synthesis 2013, MIT Press, Cambridge. S.M. Silverstein, B. Moghaddam, T. Wykes (Eds.).
85. Cournos F., McKinnon K., Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. Journal of Clinical Psychiatry 2005, 66(Suppl 6):27-33.
86. Crump C., Winkleby M.A., Sundquist K., Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry 2013, 170:324-333.
87. Dale R.C., Irani S.R., Brilot F., Pillai S., Webster R., Gill D., Lang B., Vincent A. N-methyl-d-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Annals of Neurology 2009, 66:704-709.
88. Dalman C., Allebeck P., Gunnell D., Harrison G., Kristensson K., Lewis G., Lofving S., Rasmussen F., Wicks S., Karlsson H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. American Journal of Psychiatry 2008, 165:59-65.
89. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., Dessain S.K., Rosenfeld M.R., Balice-Gordon R., Lynch D.R. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology 2008, 7:1091-1098.
90. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology 2011, 10:63-74.
91. Dalton V.S., Verdurand M., Walker A., Hodgson D.M., Zavitsanou K. Synergistic effect between maternal infection and adolescent cannabinoid exposure on serotonin 5HT1A receptor binding in the hippocampus: testing the two hit hypothesis for the development of schizophrenia. ISRN Psychiatry 2012, 2012:451865.
92. Dambinova S.A., Khounteev G.A., Izykenova G.A., Zavolokov I.G., Ilyukhina A.Y., Skoromets A.A. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clinical Chemistry 2003, 49:1752-1762.
93. Dambinova S.A., Khounteev G.A., Skoromets A.A. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke 2002, 33:1181-1182.
94. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9:46-56.
95. Dave K.A., Platel J.C., Huang F., Tian D., Stamboulian-Platel S., Bordey A. Prostaglandin E2 induces glutamate release from subventricular zone astrocytes. Neuron Glia Biology 2011, 1-7.
96. de la Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A., Codes-Manuel de Villena M.E. Cancer and immune response: old and new evidence for future challenges. Oncologist 2008, 13:1246-1254.
97. de Vries E.F., Dierckx R.A., Klein H.C. Nuclear imaging of inflammation in neurologic and psychiatric disorders. Current Clinical Pharmacology 2006, 1:229-242.
98. Deb-Rinker P., Klempan T.A., O'Reilly R.L., Torrey E.F., Singh S.M. Molecular characterization of a MSRV-like sequence identified by RDA from monozygotic twin pairs discordant for schizophrenia. Genomics 1999, 61:133-144.
99. Dennison U., McKernan D., Cryan J., Dinan T. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychological Medicine 2012, 42:1865-1871.
100. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
101. Dickerson D.D., Wolff A.R., Bilkey D.K. Abnormal long-range neural synchrony in a maternal immune activation animal model of schizophrenia. Journal of Neuroscience 2010, 30:12424-12431.
102. Dickerson F., Lillehoj E., Stallings C., Wiley M., Origoni A., Vaughan C., Khushalani S., Sabunciyan S., Yolken R. Antibodies to retroviruses in recent onset psychosis and multi-episode schizophrenia. Schizophrenia Research 2012, 138:198-205.
103. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Archives of General Psychiatry 2003, 60:466-472.
104. Domercq M., Vazquez-Villoldo N., Matute C. Neurotransmitter signaling in the pathophysiology of microglia. Frontiers in Cellular Neuroscience 2013, 7:49.
105. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. Journal of Nuclear Medicine 2009, 50:1801-1807.
106. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer 2004, 4:11-22.
107. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., Drexhage H.A. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. International Journal of Neuropsychopharmacology 2011, 14:746-755.
108. du Bois T.M., Deng C., Huang X.F. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:878-888.
109. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annual Review of Immunology 2004, 22:329-360.
110. During M.J., Symes C.W., Lawlor P.A., Lin J., Dunning J., Fitzsimons H.L., Poulsen D., Leone P., Xu R., Dicker B.L., Lipski J., Young D. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000, 287:1453-1460.
111. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., Mortensen P.B. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. American Journal of Psychiatry 2006, 163:521-528.
112. Eaton W.W., Hayward C., Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophrenia Research 1992, 6:181-192.
113. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disorders 2010, 12:638-646.
114. Elovitz M.A., Brown A.G., Breen K., Anton L., Maubert M., Burd I. Intrauterine inflammation, insufficient to induce parturition, still evokes fetal and neonatal brain injury. International Journal of Developmental Neuroscience 2011, 29:663-671.
115. Emelia O., Amal R.N., Ruzanna Z.Z., Shahida H., Azzubair Z., Tan K.S., Noor Aadila S., Siti N.A., Aisah M.Y. Seroprevalence of anti-Toxoplasma gondii IgG antibody in patients with schizophrenia. Tropical Biomedicine 2012, 29:151-159.
116. Engel A.L., Holt G.E., Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Review of Clinical Pharmacology 2011, 4:275-289.
117. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters 2001, 313:96-98.
118. Fan X., Liu E.Y., Freudenreich O., Park J.H., Liu D., Wang J., Yi Z., Goff D., Henderson D.C. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophrenia Research 2010, 118:211-217.
119. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research 2007, 149:267-271.
120. Fan Z., Wu Y., Shen J., Ji T., Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. Journal of Psychiatric Research 2013, 47:1549-1556.
121. Feinstein A., du Boulay G., Ron M.A. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. British Journal of Psychiatry 1992, 161:680-685.
122. Fields R.D. White matter in learning, cognition and psychiatric disorders. Trends in Neurosciences 2008, 31:361-370.
123. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Molecular Psychiatry 2013, 18:206-214.
124. Fineberg A.M., Ellman L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biological Psychiatry 2013, 73:951-966.
125. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of Oncology 2012, 23(Suppl 8.):viii6-viii9.
126. Fischer H.G., Nitzgen B., Reichmann G., Gross U., Hadding U. Host cells of Toxoplasma gondii encystation in infected primary culture from mouse brain. Parasitology Research 1997, 83:637-641.
127. Fischer H.G., Nitzgen B., Reichmann G., Hadding U. Cytokine responses induced by Toxoplasma gondii in astrocytes and microglial cells. European Journal of Immunology 1997, 27:1539-1548.
128. Flegr J., Klose J., Novotna M., Berenreitterova M., Havlicek J. Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study. BMC Infectious Diseases 2009, 9:72.
129. Flegr J., Kodym P., Tolarova V. Correlation of duration of latent Toxoplasma gondii infection with personality changes in women. Biological Psychology 2000, 53:57-68.
130. Flegr J., Preiss M., Klose J., Havlicek J., Vitakova M., Kodym P. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii Dopamine, a missing link between schizophrenia and toxoplasmosis?. Biological Psychology 2003, 63:253-268.
131. Francesconi L.P., Cereser K.M., Mascarenhas R., Stertz L., Gama C.S., Belmonte-de-Abreu P. Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neuroscience Letters 2011, 502:143-146.
132. Frank M.G., Thompson B.M., Watkins L.R., Maier S.F. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain, Behavior, and Immunity 2012, 26:337-345.
133. Frew L., Sugiarto N.U., Rajagopal S.P., He J., Leask R., Norman J.E., Riley S.C., Stock S.J. The effect of omega-3 polyunsaturated fatty acids on the inflammatory response of the amnion. Prostaglandins Leukotrienes and Essential Fatty Acids 2013, 89:221-225.
134. Frodl T., Amico F. Is there an association between peripheral immune markers and structural/functional neuroimaging findings?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, (in press).
135. Fujigaki S., Saito K., Takemura M., Maekawa N., Yamada Y., Wada H., Seishima M. l-Tryptophan-l-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infection and Immunity 2002, 70:779-786.
136. Fulzele S., Pillai A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophrenia Research 2009, 115:372-373.
137. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 2012, 32:179-185.
138. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rossler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkotter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
139. Gable M.S., Gavali S., Radner A., Tilley D.H., Lee B., Dyner L., Collins A., Dengel A., Dalmau J., Glaser C.A. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. European Journal of Clinical Microbiology and Infectious Diseases 2009, 28:1421-1429.
140. Gal G., Goral A., Murad H., Gross R., Pugachova I., Barchana M., Kohn R., Levav I. Cancer in parents of persons with schizophrenia: is there a genetic protection?. Schizophrenia Research 2012, 139:189-193.
141. Gandhi R., Hayley S., Gibb J., Merali Z., Anisman H. Influence of poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors. Brain, Behavior, and Immunity 2007, 21:477-489.
142. Ganguli R., Brar J.S., Rabin B.S. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harvard Review of Psychiatry 1994, 2:70-83.
143. Ganor Y., Goldberg-Stern H., Amrom D., Lerman-Sagie T., Teichberg V.I., Pelled D., Futerman A.H., Zeev B.B., Freilinger M., Verheulpen D., Van Bogaert P., Levite M. Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy. Clinical and Developmental Immunology 2004, 11:241-252.
144. Ganor Y., Goldberg-Stern H., Lerman-Sagie T., Teichberg V.I., Levite M. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Research 2005, 65:11-22.
145. Gaughran F., O'Neill E., Sham P., Daly R.J., Shanahan F. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophrenia Research 2002, 56:235-239.
146. Gibb J., Hayley S., Poulter M.O., Anisman H. Effects of stressors and immune activating agents on peripheral and central cytokines in mouse strains that differ in stressor responsivity. Brain, Behavior, and Immunity 2011, 25:468-482.
147. Gilvarry C.M., Sham P.C., Jones P.B., Cannon M., Wright P., Lewis S.W., Bebbington P., Toone B.K., Murray R.M. Family history of autoimmune diseases in psychosis. Schizophrenia Research 1996, 19:33-40.
148. Giovanoli S., Engler H., Engler A., Richetto J., Voget M., Willi R., Winter C., Riva M.A., Mortensen P.B., Schedlowski M., Meyer U. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 2013, 339:1095-1099.
149. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Archives of General Psychiatry 2000, 57:65-73.
150. Glausier J.R., Lewis D.A. Dendritic spine pathology in schizophrenia. Neuroscience 2012, 251:90-107.
151. Gogtay N., Giedd J.N., Lusk L., Hayashi K.M., Greenstein D., Vaituzis A.C., Nugent T.F., Herman D.H., Clasen L.S., Toga A.W., Rapoport J.L., Thompson P.M. Dynamic mapping of human cortical development during childhood through early adulthood. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:8174-8179.
152. Goldacre M.J., Kurina L.M., Wotton C.J., Yeates D., Seagroat V. Schizophrenia and cancer: an epidemiological study. British Journal of Psychiatry 2005, 187:334-338.
153. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. Journal of Clinical Psychiatry 2009, 70:1078-1090.
154. Goldstein J.M., Cherkerzian S., Seidman L.J., Petryshen T.L., Fitzmaurice G., Tsuang M.T., Buka S.L. Sex-specific rates of transmission of psychosis in the New England high-risk family study. Schizophrenia Research 2011, 128:150-155.
155. Goldstein J.M., Walder D.J. Sex differences in schizophrenia: the case for developmental origins and etiological implications. The Early Course of Schizophrenia 2006, Oxford University Press, Oxford, United Kingdom. T. Sharma, P.D. Harvey (Eds.).
156. Gorwood P., Pouchot J., Vinceneux P., Puechal X., Flipo R.M., De Bandt M., Ades J. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophrenia Research 2004, 66:21-29.
157. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry 2003, 160:636-645.
158. Gould T.D., Gottesman I.I. Psychiatric endophenotypes and the development of valid animal models. Genes, Brain, and Behavior 2006, 5:113-119.
159. Grinshpoon A., Barchana M., Ponizovsky A., Lipshitz I., Nahon D., Tal O., Weizman A., Levav I. Cancer in schizophrenia: is the risk higher or lower?. Schizophrenia Research 2005, 73:333-341.
160. Guillemin G.J., Cullen K.M., Lim C.K., Smythe G.A., Garner B., Kapoor V., Takikawa O., Brew B.J. Characterization of the kynurenine pathway in human neurons. Journal of Neuroscience 2007, 27:12884-12892.
161. Harizi H., Corcuff J.B., Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends in Molecular Medicine 2008, 14:461-469.
162. Haroon F., Handel U., Angenstein F., Goldschmidt J., Kreutzmann P., Lison H., Fischer K.D., Scheich H., Wetzel W., Schluter D., Budinger E. Toxoplasma gondii actively inhibits neuronal function in chronically infected mice. PLoS ONE 2012, 7:e35516.
163. Harris L.W., Pietsch S., Cheng T.M., Schwarz E., Guest P.C., Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS ONE 2012, 7:e46368.
164. Hata A.N., Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology and Therapeutics 2004, 103:147-166.
165. Hayashi Y., Ishibashi H., Hashimoto K., Nakanishi H. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia 2006, 53:660-668.
166. Hayes E., Gavrilidis E., Kulkarni J. The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia. Schizophrenia Research and Treatment 2012, 2012:540273.
167. He Y., Yu Z., Giegling I., Xie L., Hartmann A.M., Prehn C., Adamski J., Kahn R., Li Y., Illig T., Wang-Sattler R., Rujescu D. Schizophrenia shows a unique metabolomics signature in plasma. Translational Psychiatry 2012, 2:e149.
168. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophrenia Bulletin 2010, 36:472-485.
169. Hermes G., Ajioka J.W., Kelly K.A., Mui E., Roberts F., Kasza K., Mayr T., Kirisits M.J., Wollmann R., Ferguson D.J., Roberts C.W., Hwang J.H., Trendler T., Kennan R.P., Suzuki Y., Reardon C., Hickey W.F., Chen L., McLeod R. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. Journal of Neuroinflammation 2008, 5:48.
170. Hickie I.B., Banati R., Stewart C.H., Lloyd A.R. Are common childhood or adolescent infections risk factors for schizophrenia and other psychotic disorders?. Medical Journal of Australia 2009, 190:S17-S21.
171. Hippisley-Cox J., Vinogradova Y., Coupland C., Parker C. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Archives of General Psychiatry 2007, 64:1368-1376.
172. Hjorth E., Freund-Levi Y. Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid. Current Opinion in Clinical Nutrition and Metabolic Care 2012, 15:134-143.
173. Hodgson R., Wildgust H.J., Bushe C.J. Cancer and schizophrenia: is there a paradox. Journal of Psychopharmacology 2010, 24:51-60.
174. Hoek H.W., Brown A.S., Susser E. The Dutch famine and schizophrenia spectrum disorders. Social Psychiatry and Psychiatric Epidemiology 1998, 33:373-379.
175. Hoen W.P., Lijmer J.G., Duran M., Wanders R.J., van Beveren N.J., de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Research 2013, 207:1-12.
176. Hoffman D.R., Boettcher J.A., Diersen-Schade D.A. Toward optimizing vision and cognition in term infants by dietary docosahexaenoic and arachidonic acid supplementation: a review of randomized controlled trials. Prostaglandins Leukotrienes and Essential Fatty Acids 2009, 81:151-158.
177. Hoffman R.E., McGlashan T.H. Parallel distributed processing and the emergence of schizophrenic symptoms. Schizophrenia Bulletin 1993, 19:119-140.
178. Hoistad M., Segal D., Takahashi N., Sakurai T., Buxbaum J.D., Hof P.R. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Frontiers in Neuroanatomy 2009, 3:9.
179. Holtze M., Asp L., Schwieler L., Engberg G., Karlsson H. Induction of the kynurenine pathway by neurotropic influenza A virus infection. Journal of Neuroscience Research 2008, 86:3674-3683.
180. Holub D., Flegr J., Dragomirecka E., Rodriguez M., Preiss M., Novak T., Cermak J., Horacek J., Kodym P., Libiger J., Hoschl C., Motlova L.B. Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia. Acta Psychiatrica Scandinavica 2013, 127:227-238.
181. Hope S., Ueland T., Steen N.E., Dieset I., Lorentzen S., Berg A.O., Agartz I., Aukrust P., Andreassen O.A. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophrenia Research 2013, 145:36-42.
182. Horacek J., Flegr J., Tintera J., Verebova K., Spaniel F., Novak T., Brunovsky M., Bubenikova-Valesova V., Holub D., Palenicek T., Hoschl C. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World Journal of Biological Psychiatry 2012, 13:501-509.
183. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Current Opinion in Rheumatology 2013, 25:488-795.
184. Horrobin D.F. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukotrienes and Essential Fatty Acids 1996, 55:3-7.
185. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research 1998, 30:193-208.
186. Hou R., Baldwin D.S. A neuroimmunological perspective on anxiety disorders. Human Psychopharmacology 2012, 27:6-14.
187. Hua J.Y., Smith S.J. Neural activity and the dynamics of central nervous system development. Nature Neuroscience 2004, 7:327-332.
188. Huang W., Li S., Hu Y., Yu H., Luo F., Zhang Q., Zhu F. Implication of the env gene of the human endogenous retrovirus W family in the expression of BDNF and DRD3 and development of recent-onset schizophrenia. Schizophrenia Bulletin 2011, 37:988-1000.
189. Hughes E.G., Peng X., Gleichman A.J., Lai M., Zhou L., Tsou R., Parsons T.D., Lynch D.R., Dalmau J., Balice-Gordon R.J. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. Journal of Neuroscience 2010, 30:5866-5875.
190. Iizuka T., Sakai F., Ide T., Monzen T., Yoshii S., Iigaya M., Suzuki K., Lynch D.R., Suzuki N., Hata T., Dalmau J. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008, 70:504-511.
191. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., Friese M.A., Galea I., Kullmann D.M., Beeson D., Lang B., Bien C.G., Vincent A. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
192. Itzhaki R.F., Wozniak M.A., Appelt D.M., Balin B.J. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiology of Aging 2004, 25:619-627.
193. Jamieson S.E., de Roubaix L.A., Cortina-Borja M., Tan H.K., Mui E.J., Cordell H.J., Kirisits M.J., Miller E.N., Peacock C.S., Hargrave A.C., Coyne J.J., Boyer K., Bessieres M.H., Buffolano W., Ferret N., Franck J., Kieffer F., Meier P., Nowakowska D.E., Paul M., Peyron F., Stray-Pedersen B., Prusa A.R., Thulliez P., Wallon M., Petersen E., McLeod R., Gilbert R.E., Blackwell J.M. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS ONE 2008, 3:e2285.
194. Ji J., Sundquist K., Ning Y., Kendler K.S., Sundquist J., Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophrenia Bulletin 2013, 39:527-536.
195. Jones K.A., Thomsen C. The role of the innate immune system in psychiatric disorders. Molecular and Cellular Neurosciences 2013, 53:52-62.
196. Juckel G., Manitz M.P., Brune M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammational animal model of schizophrenia - a pilot study. Schizophrenia Research 2011, 131:96-100.
197. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., Krishnan K.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry 2007, 12:934-945.
198. Kale A., Naphade N., Sapkale S., Kamaraju M., Pillai A., Joshi S., Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Research 2010, 175:47-53.
199. Kannan G., Pletnikov M.V. Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspective. Schizophrenia Bulletin 2012, 38:1155-1161.
200. Karlsson H., Bachmann S., Schroder J., McArthur J., Torrey E.F., Yolken R.H. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4634-4639.
201. Karlsson H., Blomstrom A., Wicks S., Yang S., Yolken R.H., Dalman C. Maternal antibodies to dietary antigens and risk for nonaffective psychosis in offspring. American Journal of Psychiatry 2012, 169:625-632.
202. Katafuchi T., Duan S., Take S., Yoshimura M. Modulation of glutamate-induced outward current by prostaglandin E(2) in rat dissociated preoptic neurons. Brain Research 2005, 1037:180-186.
203. Khandaker G.M., Zimbron J., Dalman C., Lewis G., Jones P.B. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophrenia Research 2012, 139:161-168.
204. Khansari P.S., Sperlagh B. Inflammation in neurological and psychiatric diseases. Inflammopharmacology 2012, 20:103-107.
205. Kim H.S., Ahn K., Kim D.S. Quantitative expression of the HERV-W env gene in human tissues. Archives of Virology 2008, 153:1587-1591.
206. Kim H.Y., Moon H.S., Cao D., Lee J., Kevala K., Jun S.B., Lovinger D.M., Akbar M., Huang B.X. N-Docosahexaenoylethanolamide promotes development of hippocampal neurons. Biochemical Journal 2011, 435:327-336.
207. Knight J.G., Menkes D.B., Highton J., Adams D.D. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Molecular Psychiatry 2007, 12:424-431.
208. Korotkova M., Daha N.A., Seddighzadeh M., Ding B., Catrina A.I., Lindblad S., Huizinga T.W., Toes R.E., Alfredsson L., Klareskog L., Jakobsson P.J., Padyukov L. Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis. European Journal of Human Genetics 2011, 19:908-914.
209. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., Moons L., Wei S., Zou L., Machelon V., Emilie D., Terrassa M., Lackner A., Curiel T.J., Carmeliet P., Zou W. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Research 2005, 65:465-472.
210. Kulkarni J., Gavrilidis E., Worsley R., Hayes E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs 2012, 26:549-557.
211. Kunz M., Cereser K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira de Psiquiatria 2011, 33:268-274.
212. Laan W., Smeets H., de Wit N.J., Kahn R.S., Grobbee D.E., Burger H. Glucocorticosteroids associated with a decreased risk of psychosis. Journal of Clinical Psychopharmacology 2009, 29:288-290.
213. Lacosta S., Merali Z., Anisman H. Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects. Brain Research 1999, 818:291-303.
214. Lai M., Hughes E.G., Peng X., Zhou L., Gleichman A.J., Shu H., Mata S., Kremens D., Vitaliani R., Geschwind M.D., Bataller L., Kalb R.G., Davis R., Graus F., Lynch D.R., Balice-Gordon R., Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Annals of Neurology 2009, 65:424-434.
215. Lai M., Huijbers M.G., Lancaster E., Graus F., Bataller L., Balice-Gordon R., Cowell J.K., Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurology 2010, 9:776-785.
216. Lancaster E., Lai M., Peng X., Hughes E., Constantinescu R., Raizer J., Friedman D., Skeen M.B., Grisold W., Kimura A., Ohta K., Iizuka T., Guzman M., Graus F., Moss S.J., Balice-Gordon R., Dalmau J. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurology 2010, 9:67-76.
217. Lang C., Gross U., Luder C.G. Subversion of innate and adaptive immune responses by Toxoplasma gondii. Parasitology Research 2007, 100:191-203.
218. Latour A., Grintal B., Champeil-Potokar G., Hennebelle M., Lavialle M., Dutar P., Potier B., Billard J.M., Vancassel S., Denis I. Omega-3 fatty acids deficiency aggravates glutamatergic synapse and astroglial aging in the rat hippocampal CA1. Aging Cell 2013, 12:76-84.
219. Lauvsnes M.B., Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. Journal of Neurology 2012, 259:622-629.
220. Laye S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins Leukotrienes and Essential Fatty Acids 2010, 82:295-303.
221. Leboyer M., Tamouza R., Charron D., Faucard R., Perron H. Human endogenous retrovirus type W (HERV-W) in schizophrenia: a new avenue of research at the gene-environment interface. World Journal of Biological Psychiatry 2013, 14:80-90.
222. Lees-Murdock D.J., Walsh C.P. DNA methylation reprogramming in the germ line. Epigenetics 2008, 3:5-13.
223. Lees M.P., Fuller S.J., McLeod R., Boulter N.R., Miller C.M., Zakrzewski A.M., Mui E.J., Witola W.H., Coyne J.J., Hargrave A.C., Jamieson S.E., Blackwell J.M., Wiley J.S., Smith N.C. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. Journal of Immunology 2010, 184:7040-7046.
224. Leonard B.E., Schwarz M., Myint A.M. The metabolic syndrome in schizophrenia: is inflammation a contributing cause. Journal of Psychopharmacology 2012, 26:33-41.
225. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 2007, 116:317-333.
226. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica Supplementum 2000, 401:3-38.
227. Levav I., Lipshitz I., Novikov I., Pugachova I., Kohn R., Barchana M., Ponizovsky A., Werner H. Cancer risk among parents and siblings of patients with schizophrenia. British Journal of Psychiatry 2007, 190:156-161.
228. Levesque M., Potvin S., Marchand S., Stip E., Grignon S., Pierre L., Lipp O., Goffaux P. Pain perception in schizophrenia: evidence of a specific pain response profile. Pain Medicine 2012, 13:1571-1579.
229. Leweke F.M., Gerth C.W., Koethe D., Klosterkotter J., Ruslanova I., Krivogorsky B., Torrey E.F., Yolken R.H. Antibodies to infectious agents in individuals with recent onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2004, 254:4-8.
230. Lichtermann D., Ekelund J., Pukkala E., Tanskanen A., Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Archives of General Psychiatry 2001, 58:573-578.
231. Lim S.Y., Hoshiba J., Moriguchi T., Salem N. N-3 fatty acid deficiency induced by a modified artificial rearing method leads to poorer performance in spatial learning tasks. Pediatric Research 2005, 58:741-748.
232. Lin C.H., Lane H.Y., Tsai G.E. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology. Biochemistry and Behavior 2012, 100:665-677.
233. Lin C.Y., Lane H.Y., Chen T.T., Wu Y.H., Wu C.Y., Wu V.Y. Inverse association between cancer risks and age in schizophrenic patients: a 12-year nationwide cohort study. Cancer Science 2013, 104:383-390.
234. Lin G.M., Chen Y.J., Kuo D.J., Jaiteh L.E., Wu Y.C., Lo T.S., Li Y.H. Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997-2009. Schizophrenia Bulletin 2013, 39:407-416.
235. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Samuelsson M., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophrenia Bulletin 2012, 38:426-432.
236. Ling V.J., Lester D., Mortensen P.B., Langenberg P.W., Postolache T.T. Toxoplasma gondii seropositivity and suicide rates in women. Journal of Nervous and Mental Disease 2011, 199:440-444.
237. Lipina T.V., Zai C., Hlousek D., Roder J.C., Wong A.H. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. Journal of Neuroscience 2013, 33:7654-7666.
238. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences 2008, 31:234-242.
239. Lokesh B.R., Hsieh H.L., Kinsella J.E. Peritoneal macrophages from mice fed dietary (n-3) polyunsaturated fatty acids secrete low levels of prostaglandins. Journal of Nutrition 1986, 116:2547-2552.
240. Luder C.G., Algner M., Lang C., Bleicher N., Gross U. Reduced expression of the inducible nitric oxide synthase after infection with Toxoplasma gondii facilitates parasite replication in activated murine macrophages. International Journal for Parasitology 2003, 33:833-844.
241. Luder C.G., Lang T., Beuerle B., Gross U. Down-regulation of MHC class II molecules and inability to up-regulate class I molecules in murine macrophages after infection with Toxoplasma gondii. Clinical and Experimental Immunology 1998, 112:308-316.
242. Lung F.W., Shu B.C., Kao W.T., Chen C.N., Ku Y.C., Tzeng D.S. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Medical Genetics 2009, 10:147.
243. Mandi Y., Vecsei L. The kynurenine system and immunoregulation. Journal of Neural Transmission 2012, 119:197-209.
244. Mann A., Machado N.M., Liu N., Mazin A.H., Silver K., Afzal K.I. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: a case and review of the literature. Journal of Neuropsychiatry and Clinical Neurosciences 2012, 24:247-254.
245. Marrie R.A., Horwitz R., Cutter G., Tyry T., Campagnolo D., Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Multiple Sclerosis 2009, 15:385-392.
246. Martinez-Gras I., Garcia-Sanchez F., Guaza C., Rodriguez-Jimenez R., Andres-Esteban E., Palomo T., Rubio G., Borrell J. Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Research 2012, 200:1022-1025.
247. Martinez-Gras I., Perez-Nievas B.G., Garcia-Bueno B., Madrigal J.L., Andres-Esteban E., Rodriguez-Jimenez R., Hoenicka J., Palomo T., Rubio G., Leza J.C. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophrenia Research 2011, 128:15-22.
248. McCoy J.M., Wicks J.R., Audoly L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. Journal of Clinical Investigation 2002, 110:651-658.
249. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. Journal of Neuroscience 2004, 24:257-268.
250. McMillan K.A., Asmundson G.J., Zvolensky M.J., Carleton R.N. Startle response and anxiety sensitivity: subcortical indices of physiologic arousal and fear responding. Emotion 2012, 12:1264-1272.
251. McMurray D.N., Bonilla D.L., Chapkin R.S. n-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization. Chemistry and Physics of Lipids 2011, 164:626-635.
252. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophrenia Research 2007, 91:37-50.
253. Mesquita J., Siva L. Anti-NMDA receptor encephalitis suspected as cause of drug-induced psychosis. Journal of Neuropsychiatry and Clinical Neurosciences 2011, 23:E2.
254. Meszaros Z.S., Perl A., Faraone S.V. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. Journal of Clinical Psychiatry 2012, 73:993-1001.
255. Meyer U., Feldon J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 2012, 62:1308-1321.
256. Meyer U., Feldon J., Schedlowski M., Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neuroscience and Biobehavioral Reviews 2005, 29:913-947.
257. Meyer U., Nyffeler M., Yee B.K., Knuesel I., Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain, Behavior, and Immunity 2008, 22:469-486.
258. Meyer U., Schwarz M.J., Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology and Therapeutics 2011, 132:96-110.
259. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65:732-741.
260. Miller B., Sarantis M., Traynelis S.F., Attwell D. Potentiation of NMDA receptor currents by arachidonic acid. Nature 1992, 355:722-725.
261. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70:663-671.
262. Miller B.J., Graham K.L., Bodenheimer C.M., Culpepper N.H., Waller J.L., Buckley P.F. A prevalence study of urinary tract infections in acute relapse of schizophrenia. Journal of Clinical Psychiatry 2013, 74:271-277.
263. Miller B.J., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain, Behavior, and Immunity 2013, 31:82-89.
264. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophrenia Bulletin 2013, 39:306-318.
265. Mitchell K.J., Durstewitz P.O., Fenton A.A., Gingrich J.A., Gordon J.A., Kelsh W., Moghaddam B., Phillips W.A., Sawa A. How can models be better utlized to enhance outcome?. Schizophrenia: Evolution and Synthesis 2013, 13-34. MIT Press, Cambridge, MA. S.M. Silverstein, B. Moghaddam, T. Wykes (Eds.).
266. Molloy C., Conroy R.M., Cotter D.R., Cannon M. Is traumatic brain injury a risk factor for schizophrenia? A meta-analysis of case-controlled population-based studies. Schizophrenia Bulletin 2011, 37:1104-1110.
267. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences 2009, 63:257-265.
268. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 42:115-121.
269. Morar B., Schwab S.G., Albus M., Maier W., Lerer B., Wildenauer D.B. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. American Journal of Medical Genetics B: Neuropsychiatric Genetics 2007, 144B:318-324.
270. Morgan C., O'Donovan M., Bittner R.A., Cadenhead K.S., Jones P.B., McGrath J., Silverstein S.M., Tost H., Uhlhaas P., Voineskos A. How can risk and resilience factors be leveraged to optimize discovery pathways?. Schizophrenia: Evolution and Synthesis 2013, vol. 13:137-164. MIT Press, Cambridge.
271. Moriguchi T., Greiner R.S., Salem N. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. Journal of Neurochemistry 2000, 75:2563-2573.
272. Mors O., Mortensen P.B., Ewald H. A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophrenia Research 1999, 40:67-74.
273. Mortensen P.B. The incidence of cancer in schizophrenic patients. Journal of Epidemiology and Community Health 1989, 43:43-47.
274. Mortensen P.B., Norgaard-Pedersen B., Waltoft B.L., Sorensen T.L., Hougaard D., Torrey E.F., Yolken R.H. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biological Psychiatry 2007, 61:688-693.
275. Mortensen P.B., Norgaard-Pedersen B., Waltoft B.L., Sorensen T.L., Hougaard D., Yolken R.H. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophrenia Bulletin 2007, 33:741-744.
276. Muller N., Myint A.M., Krause D., Weidinger E., Schwarz M.J. Anti-inflammatory treatment in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 42:146-153.
277. Muller N., Myint A.M., Schwarz M.J. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders - relation to drug treatment. Dialogues in Clinical Neuroscience 2009, 11:319-332.
278. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research 2006, 10:131-148.
279. Muller N., Ulmschneider M., Scheppach C., Schwarz M.J., Ackenheil M., Moller H.J., Gruber R., Riedel M. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry and Clinical Neuroscience 2004, 254:14-22.
280. Murphy M.A., O'Leary J.J., Cahill D.J. Assessment of the humoral immune response to cancer. Journal of Proteomics 2012, 75:4573-4579.
281. Nellaker C., Yao Y., Jones-Brando L., Mallet F., Yolken R.H., Karlsson H. Transactivation of elements in the human endogenous retrovirus W family by viral infection. Retrovirology 2006, 3:44.
282. Ni X., Trakalo J., Valente J., Azevedo M.H., Pato M.T., Pato C.N., Kennedy J.L. Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control and family studies. Neuroscience Letters 2005, 388:173-178.
283. Nilsson L.K., Linderholm K.R., Engberg G., Paulson L., Blennow K., Lindstrom L.H., Nordin C., Karanti A., Persson P., Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Research 2005, 80:315-322.
284. Nishikawa M., Kimura S., Akaike N. Facilitatory effect of docosahexaenoic acid on N-methyl-d-aspartate response in pyramidal neurones of rat cerebral cortex. Journal of Physiology 1994, 475:83-93.
285. Nunes S.O., Matsuo T., Kaminami M.S., Watanabe M.A., Reiche E.M., Itano E.N. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophrenia Research 2006, 84:180-182.
286. Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmunity Reviews 2012, 11:A486-A492.
287. Oken R.J., Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophrenia Bulletin 1999, 25:625-638.
288. Okusaga O., Langenberg P., Sleemi A., Vaswani D., Giegling I., Hartmann A.M., Konte B., Friedl M., Groer M.W., Yolken R.H., Rujescu D., Postolache T.T. Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophrenia Research 2011, 133:150-155.
289. Oskvig D.B., Elkahloun A.G., Johnson K.R., Phillips T.M., Herkenham M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain, Behavior, and Immunity 2012, 26:623-634.
290. Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Giustetto M., Ferreira T.A., Guiducci E., Dumas L., Ragozzino D., Gross C.T. Synaptic pruning by microglia is necessary for normal brain development. Science 2011, 333:1456-1458.
291. Park J.K., Lee H.J., Kim J.W., Park Y.H., Lee S.S., Chang H.I., Song J.Y., Yoon D.J., Bahn G.H., Shin Y.H., Kim Y.J., Kim S.A., Choe B.K., Kim C.J., Chung J.H. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophrenia Research 2004, 67:71-74.
292. Park M.H., Kwon Y.J., Jeong H.Y., Lee H.Y., Hwangbo Y., Yoon H.J., Shim S.H. Association between Intracellular Infectious Agents and Schizophrenia. Clinical Psychopharmacology and Neuroscience 2012, 10:117-123.
293. Pasternak O., Westin C.F., Bouix S., Seidman L.J., Goldstein J.M., Woo T.U., Petryshen T.L., Mesholam-Gately R.I., McCarley R.W., Kikinis R., Shenton M.E., Kubicki M. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. Journal of Neuroscience 2012, 32:17365-17372.
294. Pavone P., Parano E., Rizzo R., Trifiletti R.R. Autoimmune neuropsychiatric disorders associated with streptococcal infection: Sydenham chorea, PANDAS, and PANDAS variants. Journal of Child Neurology 2006, 21:727-736.
295. Pedersen M.G., Stevens H., Pedersen C.B., Norgaard-Pedersen B., Mortensen P.B. Toxoplasma infection and later development of schizophrenia in mothers. American Journal of Psychiatry 2011, 168:814-821.
296. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., Teixeira A.L., Lobato M.I., Walz J.C., Belmonte-de-Abreu P.S., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research 2012, 46:819-824.
297. Perron H., Hamdani N., Faucard R., Lajnef M., Jamain S., Daban-Huard C., Sarrazin S., Leguen E., Houenou J., Delavest M., Moins-Teiserenc H., Bengoufa D., Yolken R., Madeira A., Garcia-Montojo M., Gehin N., Burgelin I., Ollagnier G., Bernard C., Dumaine A., Henrion A., Gombert A., Le Dudal K., Charron D., Krishnamoorthy R., Tamouza R., Leboyer M. Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder. Translational Psychiatry 2013, 3:e226.
298. Perron H., Jouvin-Marche E., Michel M., Ounanian-Paraz A., Camelo S., Dumon A., Jolivet-Reynaud C., Marcel F., Souillet Y., Borel E., Gebuhrer L., Santoro L., Marcel S., Seigneurin J.M., Marche P.N., Lafon M. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology 2001, 287:321-332.
299. Perron H., Mekaoui L., Bernard C., Veas F., Stefas I., Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biological Psychiatry 2008, 64:1019-1023.
300. Phillips W.A., Silverstein S.M. Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behavioral and Brain Sciences 2003, 26:65-82. (discussion 82-137).
301. Pleasure D. Diagnostic and pathogenic significance of glutamate receptor autoantibodies. Archives of Neurology 2008, 65:589-592.
302. Pocivavsek A., Wu H.Q., Elmer G.I., Bruno J.P., Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. European Journal of Neuroscience 2012, 35:1605-1612.
303. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
304. Prandovszky E., Gaskell E., Martin H., Dubey J.P., Webster J.P., McConkey G.A. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS ONE 2011, 6:e23866.
305. Prasad K.M., Eack S.M., Goradia D., Pancholi K.M., Keshavan M.S., Yolken R.H., Nimgaonkar V.L. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. American Journal of Psychiatry 2011, 168:822-830.
306. Prasad K.M., Shirts B.H., Yolken R.H., Keshavan M.S., Nimgaonkar V.L. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Molecular Psychiatry 2007, 12:105-113.
307. Prokop S., Miller K.R., Heppner F.L. Microglia actions in Alzheimer's disease. Acta Neuropathologica 2013, 126:461-477.
308. Pruss H., Dalmau J., Harms L., Holtje M., Ahnert-Hilger G., Borowski K., Stoecker W., Wandinger K.P. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010, 75:1735-1739.
309. Pruss H., Holtje M., Maier N., Gomez A., Buchert R., Harms L., Ahnert-Hilger G., Schmitz D., Terborg C., Kopp U., Klingbeil C., Probst C., Kohler S., Schwab J.M., Stoecker W., Dalmau J., Wandinger K.P. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 78:1743-1753.
310. Ramos-Loyo J., Medina-Hernandez V., Estarron-Espinosa M., Canales-Aguirre A., Gomez-Pinedo U., Cerdan-Sanchez L.F. Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 44:154-161.
311. Rao J.S., Kim H.W., Harry G.J., Rapoport S.I., Reese E.A. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophrenia Research 2013, 147:24-31.
312. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry 2012, 17:1228-1238.
313. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:986-1000.
314. Richard M.D., Brahm N.C. Schizophrenia and the immune system: pathophysiology, prevention, and treatment. American Journal of Health-System Pharmacy 2012, 69:757-766.
315. Richetto J., Calabrese F., Riva M.A., Meyer U. Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome. Schizophrenia Bulletin 2013, (in press).
316. Robinson C.M., Hale P.T., Carlin J.M. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. Journal of Interferon and Cytokine Research 2005, 25:20-30.
317. Rolland A., Jouvin-Marche E., Viret C., Faure M., Perron H., Marche P.N. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. Journal of Immunology 2006, 176:7636-7644.
318. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematology 2007, 62:179-213.
319. Rothschild D.M., O'Grady M., Wecker L. Neonatal cytomegalovirus exposure decreases prepulse inhibition in adult rats: implications for schizophrenia. Journal of Neuroscience Research 1999, 57:429-434.
320. Roumier A., Pascual O., Bechade C., Wakselman S., Poncer J.C., Real E., Triller A., Bessis A. Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoS ONE 2008, 3:e2595.
321. Rozenfeld C., Martinez R., Seabra S., Sant'anna C., Goncalves J.G., Bozza M., Moura-Neto V., De Souza W. Toxoplasma gondii prevents neuron degeneration by interferon-gamma-activated microglia in a mechanism involving inhibition of inducible nitric oxide synthase and transforming growth factor-beta1 production by infected microglia. American Journal of Pathology 2005, 167:1021-1031.
322. Ryan A.S., Astwood J.D., Gautier S., Kuratko C.N., Nelson E.B., Salem N. Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: a review of human studies. Prostaglandins Leukotrienes and Essential Fatty Acids 2010, 82:305-314.
323. SanGiovanni J.P., Parra-Cabrera S., Colditz G.A., Berkey C.S., Dwyer J.T. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. Pediatrics 2000, 105:1292-1298.
324. Sanzgiri R.P., Araque A., Haydon P.G. Prostaglandin E(2) stimulates glutamate receptor-dependent astrocyte neuromodulation in cultured hippocampal cells. Journal of Neurobiology 1999, 41:221-229.
325. Sathyasaikumar K.V., Stachowski E.K., Wonodi I., Roberts R.C., Rassoulpour A., McMahon R.P., Schwarcz R. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophrenia Bulletin 2011, 37:1147-1156.
326. Schafer D.P., Stevens B. Synapse elimination during development and disease: immune molecules take centre stage. Biochemical Society Transactions 2010, 38:476-481.
327. Schenkel L.S., Silverstein S.M. Dimensions of premorbid functioning in schizophrenia: a review of neuromotor, cognitive, social, and behavioral domains. Genetic, Social, and General Psychology Monographs 2004, 130:241-270.
328. Schmitz G., Ecker J. The opposing effects of n-3 and n-6 fatty acids. Progress in Lipid Research 2008, 47:147-155.
329. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
330. Schretlen D.J., Vannorsdall T.D., Winicki J.M., Mushtaq Y., Hikida T., Sawa A., Yolken R.H., Dickerson F.B., Cascella N.G. Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. Schizophrenia Research 2010, 118:224-231.
331. Schwarcz R., Hunter C.A. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?. Schizophrenia Bulletin 2007, 33:652-653.
332. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biological Psychiatry 2001, 50:521-530.
333. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., McAllister G., Spain M., Barnes A., van Beveren N.J., Baron-Cohen S., Steiner J., Torrey F.E., Yolken R.H., Bahn S. Identification of a biological signature for schizophrenia in serum. Molecular Psychiatry 2012, 17:494-502.
334. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Medical Hypotheses 2001, 56:483-486.
335. Schwieler L., Erhardt S., Erhardt C., Engberg G. Prostaglandin-mediated control of rat brain kynurenic acid synthesis - opposite actions by COX-1 and COX-2 isoforms. Journal of Neural Transmission 2005, 112:863-872.
336. Shaikh S.R., Jolly C.A., Chapkin R.S. n-3 Polyunsaturated fatty acids exert immunomodulatory effects on lymphocytes by targeting plasma membrane molecular organization. Molecular Aspects of Medicine 2012, 33:46-54.
337. Shepherd A.M., Laurens K.R., Matheson S.L., Carr V.J., Green M.J. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neuroscience and Biobehavioral Reviews 2012, 36:1342-1356.
338. Shi L., Fatemi S.H., Sidwell R.W., Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. Journal of Neuroscience 2003, 23:297-302.
339. Shi L., Smith S.E., Malkova N., Tse D., Su Y., Patterson P.H. Activation of the maternal immune system alters cerebellar development in the offspring. Brain, Behavior, and Immunity 2009, 23:116-123.
340. Shi L., Tu N., Patterson P.H. Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. International Journal of Developmental Neuroscience 2005, 23:299-305.
341. Shirts B.H., Kim J.J., Reich S., Dickerson F.B., Yolken R.H., Devlin B., Nimgaonkar V.L. Polymorphisms in MICB are associated with human herpes virus seropositivity and schizophrenia risk. Schizophrenia Research 2007, 94:342-353.
342. Short S.J., Lubach G.R., Karasin A.I., Olsen C.W., Styner M., Knickmeyer R.C., Gilmore J.H., Coe C.L. Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey. Biological Psychiatry 2010, 67:965-973.
343. Sideli L., Mule A., La Barbera D., Murray R.M. Do child abuse and maltreatment increase risk of schizophrenia?. Psychiatry Investigation 2012, 9:87-99.
344. Sigurdsson T., Stark K.L., Karayiorgou M., Gogos J.A., Gordon J.A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 2010, 464:763-767.
345. Silva N.M., Rodrigues C.V., Santoro M.M., Reis L.F., Alvarez-Leite J.I., Gazzinelli R.T. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infection and Immunity 2002, 70:859-868.
346. Simopoulos A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Experimental Biology and Medicine (Maywood, NJ) 2008, 233:674-688.
347. Skosnik P.D., Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins Leukotrienes and Essential Fatty Acids 2003, 69:367-384.
348. Smesny S. Prostaglandin-mediated signaling in schizophrenia. International Review of Neurobiology 2004, 59:255-271.
349. Smesny S., Milleit B., Nenadic I., Preul C., Kinder D., Lasch J., Willhardt I., Sauer H., Gaser C. Phospholipase A2 activity is associated with structural brain changes in schizophrenia. Neuroimage 2010, 52:1314-1327.
350. Smith H.S. Arachidonic acid pathways in nociception. Journal of Supportive Oncology 2006, 4:277-287.
351. Sominsky L., Fuller E.A., Bondarenko E., Ong L.K., Averell L., Nalivaiko E., Dunkley P.R., Dickson P.W., Hodgson D.M. Functional programming of the autonomic nervous system by early life immune exposure: implications for anxiety. PLoS ONE 2013, 8:e57700.
352. Sommer I.E., de Witte L., Begemann M., Kahn R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. Journal of Clinical Psychiatry 2012, 73:414-419.
353. Soumiya H., Fukumitsu H., Furukawa S. Prenatal immune challenge compromises development of upper-layer but not deeper-layer neurons of the mouse cerebral cortex. Journal of Neuroscience Research 2011, 89:1342-1350.
354. Spudich S.S., Ances B.M. Neurologic complications of HIV infection. Topics in Antiviral Medicine 2012, 20:41-47.
355. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. Journal of Psychiatric Research 2008, 42:151-157.
356. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., Bogerts B. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathologica 2006, 112:305-316.
357. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.G., Vielhaber S., Kastner A., Skalej M., Jordan W., Schiltz K., Klingbeil C., Wandinger K.P., Bogerts B., Stoecker W. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70:271-278.
358. Strom J.O., Theodorsson A., Theodorsson E. Mechanisms of estrogens' dose-dependent neuroprotective and neurodamaging effects in experimental models of cerebral ischemia. International Journal of Molecular Sciences 2011, 12:1533-1562.
359. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. Journal of Autoimmunity 2006, 27:71-80.
360. Sumiyoshi T., Matsui M., Itoh H., Higuchi Y., Arai H., Takamiya C., Kurachi M. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Research 2008, 157:87-93.
361. Susser E., Hoek H.W., Brown A. Neurodevelopmental disorders after prenatal famine: the story of the Dutch Famine Study. American Journal of Epidemiology 1998, 147:213-216.
362. Suzuki Y., Wong S.Y., Grumet F.C., Fessel J., Montoya J.G., Zolopa A.R., Portmore A., Schumacher-Perdreau F., Schrappe M., Koppen S., Ruf B., Brown B.W., Remington J.S. Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. Journal of Infectious Diseases 1996, 173:265-268.
363. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008, 199:331-388.
364. Takahashi Y., Mori H., Mishina M., Watanabe M., Fujiwara T., Shimomura J., Aiba H., Miyajima T., Saito Y., Nezu A., Nishida H., Imai K., Sakaguchi N., Kondo N. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 2003, 61:891-896.
365. Takaki J., Fujimori K., Miura M., Suzuki T., Sekino Y., Sato K. l-Glutamate released from activated microglia downregulates astrocytic l-glutamate transporter expression in neuroinflammation: the 'collusion' hypothesis for increased extracellular l-glutamate concentration in neuroinflammation. Journal of Neuroinflammation 2012, 9:275.
366. Tang B., Capitao C., Dean B., Thomas E.A. Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Research 2012, 196:201-206.
367. Tenenbaum M., Azab A.N., Kaplanski J. Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures. Journal of Endotoxin Research 2007, 13:158-166.
368. Tenter A.M., Heckeroth A.R., Weiss L.M. Toxoplasma gondii: from animals to humans. International Journal for Parasitology 2000, 30:1217-1258.
369. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 2007, 33:729-736.
370. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophrenia Bulletin 2012, 38:642-647.
371. Torrey E.F., Yolken R.H. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?. Brain, Behavior, and Immunity 2001, 15:401-410.
372. Tremblay M.E., Stevens B., Sierra A., Wake H., Bessis A., Nimmerjahn A. The role of microglia in the healthy brain. Journal of Neuroscience 2011, 31:16064-16069.
373. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biological Psychiatry 2008, 64:820-822.
374. van der Kemp W.J., Klomp D.W., Kahn R.S., Luijten P.R., Hulshoff Pol H.E. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophrenia Research 2012, 141:153-161.
375. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biological Psychiatry 2008, 63:106-113.
376. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
377. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophrenia Bulletin 2008, 34:1066-1082.
378. Wake H., Moorhouse A.J., Jinno S., Kohsaka S., Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. Journal of Neuroscience 2009, 29:3974-3980.
379. Walker A.K., Nakamura T., Byrne R.J., Naicker S., Tynan R.J., Hunter M., Hodgson D.M. Neonatal lipopolysaccharide and adult stress exposure predisposes rats to anxiety-like behaviour and blunted corticosterone responses: implications for the double-hit hypothesis. Psychoneuroendocrinology 2009, 34:1515-1525.
380. Wallace T.L., Ballard T.M., Pouzet B., Riedel W.J., Wettstein J.G. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacology Biochemistry and Behavior 2011, 99:130-145.
381. Walterfang M., Velakoulis D., Whitford T.J., Pantelis C. Understanding aberrant white matter development in schizophrenia: an avenue for therapy?. Expert Review of Neurotherapeutics 2011, 11:971-987.
382. Wandinger K.P., Saschenbrecker S., Stoecker W., Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. Journal of Neuroimmunology 2011, 231:86-91.
383. Watanabe Y., Nunokawa A., Kaneko N., Muratake T., Arinami T., Ujike H., Inada T., Iwata N., Kunugi H., Itokawa M., Otowa T., Ozaki N., Someya T. Two-stage case-control association study of polymorphisms in rheumatoid arthritis susceptibility genes with schizophrenia. Journal of Human Genetics 2009, 54:62-65.
384. Webster J.P. The effect of Toxoplasma gondii on animal behavior: playing cat and mouse. Schizophrenia Bulletin 2007, 33:752-756.
385. Westman M., Korotkova M., Af Klint E., Stark A., Audoly L.P., Klareskog L., Ulfgren A.K., Jakobsson P.J. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis and Rheumatism 2004, 50:1774-1780.
386. Wierzba-Bobrowicz T., Lewandowska E., Lechowicz W., Stepien T., Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathologica 2005, 43:81-89.
387. Willette A.A., Lubach G.R., Knickmeyer R.C., Short S.J., Styner M., Gilmore J.H., Coe C.L. Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. Behavioural Brain Research 2011, 219:108-115.
388. Williamson L.L., Sholar P.W., Mistry R.S., Smith S.H., Bilbo S.D. Microglia and memory: modulation by early-life infection. Journal of Neuroscience 2011, 31:15511-15521.
389. Wright P., Sham P.C., Gilvarry C.M., Jones P.B., Cannon M., Sharma T., Murray R.M. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophrenia Research 1996, 20:261-267.
390. Yang J., Chen T., Sun L., Zhao Z., Qi X., Zhou K., Cao Y., Wang X., Qiu Y., Su M., Zhao A., Wang P., Yang P., Wu J., Feng G., He L., Jia W., Wan C. Potential metabolite markers of schizophrenia. Molecular Psychiatry 2013, 18:67-78.
391. Yao J., Stanley J.A., Reddy R.D., Keshavan M.S., Pettegrew J.W. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biological Psychiatry 2002, 52:823-830.
392. Yao Y., Schroder J., Nellaker C., Bottmer C., Bachmann S., Yolken R.H., Karlsson H. Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia. Genes, Brain, and Behavior 2008, 7:103-112.
393. Yin D.M., Chen Y.J., Sathyamurthy A., Xiong W.C., Mei L. Synaptic dysfunction in schizophrenia. Advances in Experimental Medicine and Biology 2012, 970:493-516.
394. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain, Behavior, and Immunity 2011, 25:181-213.
395. Yolken R.H., Bachmann S., Ruslanova I., Lillehoj E., Ford G., Torrey E.F., Schroeder J. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clinical Infectious Diseases 2001, 32:842-844.
396. Yolken R.H., Dickerson F.B., Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunology 2009, 31:706-715.
397. Yolken R.H., Torrey E.F., Lieberman J.A., Yang S., Dickerson F.B. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophrenia Research 2011, 128:61-65.
398. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., Coles A.J., Vincent A., Lennox B.R. Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology 2011, 258:686-688.
399. Zheng D., Zhou D., Zhao Z., Liu Z., Xiao S., Xing Y., Suo W.Z., Liu J. The clinical presentation and imaging manifestation of psychosis and dementia in general paresis: a retrospective study of 116 cases. Journal of Neuropsychiatry and Clinical Neurosciences 2011, 23:300-307.